Join to view full profile
450 Brookline AveBoston, MA 02215
Phone+1 617-632-3000
Dr. Lane is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2008 - 2012- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2006 - 2008
WashU MedicineClass of 2006
Certifications & Licensure
MA State Medical License 2008 - 2027
American Board of Internal Medicine Hematology
Clinical Trials
- Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
- SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Start of enrollment: 2017 Jun 26
- Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Start of enrollment: 2018 Aug 23
Publications & Presentations
PubMed
- Hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: clinical practice guidelines from the American Society for Transplantation and Cel...Mohamed A Kharfan-Dabaja, Ambuj Kumar, Naveen Pemmaraju, Hemant Murthy, Monzr Al Malki
Transplantation and Cellular Therapy. 2026-08-18 - Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine.Evan C Chen, Yiwen Liu, Hayden L Bell, Jeremy Ryan, Jason Wu
Clinical Cancer Research. 2026-08-14 - The Clinicopathologic and Genomic Features of Mature Versus Blastic Plasmacytoid Dendritic Cell Neoplasms Arising From Chronic Myeloid Neoplasms.Sarah J Wu, Christopher B Hergott, Gabriel K Griffin, Andrew A Lane, Marlise R Luskin
The American Journal of Surgical Pathology. 2026-08-01
Abstracts/Posters
- Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic ...Andrew A. Lane, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase I Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Blastic Plasmacytoid Dendriti...Andrew A. Lane, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor P...Andrew A. Lane, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
Dana-Farber Names Division ChiefMay 26th, 2026- New Target for Potential Leukemia TherapyMay 8th, 2024
- Leukemia Relapse Could Be Prevented by Disrupting Immune Signaling MechanismMay 8th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
